CompletedPhase 2

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

United States49 participantsStarted 2008-08-08

Plain-language summary

RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion * Autologous PBSC transplant patient * English-speaking * Planned cryopreserved PBSC infusion at the SCCA outpatient clinic Exclusion * History of prior autologous transplant * Non-English-speaking * Planned cryopreserved PBSC infusion at the UWMC inpatient unit * Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion * Allergy or adverse reaction to ondansetron

What they're measuring

Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)

Timeframe: Baseline up to 120 minutes

Trial details

NCT IDNCT00795769

SponsorFred Hutchinson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-06-09

Results submitted2017-03-06

View on ClinicalTrials.gov More Accelerated Phase Chronic Myelogenous Leukemia trials